地西他滨联合小剂量阿糖胞苷治疗老年急性髓系白血病临床观察被引量：6

Clinical observation of decitabine combined with low dose cytarabine in older patients with acute myeloid leukemia

在线阅读下载PDF

导出

摘要目的观察地西他滨联合小剂量阿糖胞苷方案治疗老年急性髓系白血病的临床疗效和安全性。方法 2012年12月至2014年3月本院血液科收治的30例老年急性髓系白血病患者,其中10例采用地西他滨联合小剂量阿糖胞苷方案（地西他滨20mg/（m2·d）静脉点滴d1~5,阿糖胞苷25mg皮下注射,每12小时1次,d4~17）;其余20例仅给予阿糖胞苷25mg皮下注射,每12小时1次,d1~21,观察其临床疗效及不良反应。结果 10例应用地西他滨患者中7例完成5个周期治疗,1例完成4个周期治疗,2例完成3个周期;5例患者获完全缓解,3例获部分缓解,2例无效,最终死于严重感染。不良反应主要为骨髓抑制及恶心等胃肠道反应;20例仅用阿糖胞苷患者,只有1例达到完全缓解,5例部分缓解,其余无效。结论地西他滨联合小剂量阿糖胞苷治疗老年急性髓系白血病效果良好,明显优于单纯小剂量阿糖胞苷方案,而且不良反应少可耐受。 Objectives To explore the clinical efficacy and safety of decitabine combined with low dose cytarabine in older pa-tients with acute myeloid leukemia.Methods 30 older patients with acute myeloid leukemia treated in hematological department enrolled from December 2012 to March 2014 were collected.10 of 30 cases were treated with decitabine combined with low dose cyt-arabine [decitabine 20mg/（m2＆#183; d） intravenous drip d1~5,cytarabine 25mg subcutaneous injections q12h d4~17];The other 20 ca-ses were only treated with low dose cytarabine（25mg subcutaneous injections q12 d1~21 ）.The clinical outcome and adverse events in these patients were analyzed.Results 7 of 10 cases treated with decitabine combined with low cytarabinecompleted 5 courses, 1 of 10 cases completed 4 courses, 2 of 10 cases completed 3 courses;Among these 10 patients, 5 achieved complete remission（ CR） , 3achieved partial remission, 2 were ineffective （died of severe infection）;Among the other 20 cases treated only with low dose cyt-arabine, only 1 case achieved complete remission;5 achieved partial remission;14 were ineffective.Conclusions The proposal of decitabine combined with low dose cytarabine is more effective than that of only low dose cytarabine, and well tolerated for those ol-der patients with acute myeloid leukemia.

作者马树沛林梅

机构地区青岛市市立医院血液科青岛大学医学院病理教研室

出处《中国老年保健医学》 2015年第3期6-8,13,共4页 Chinese Journal of Geriatric Care

关键词地西他滨老年急性髓系白血病阿糖胞苷 decitabineAcute myeloid leukemia in elderly patients

分类号 R733.71 [医药卫生—肿瘤]

作者简介为通讯作者

引文网络
相关文献

参考文献12

1Kuendgen A, Germing U. Emerging treatment strategies for acute mye- loid leukemia(AML) in the elderly[ J]. Cancer Treat Rev, 2009,35(2) :97 - 120.
2陶皓珣,徐建民.CAG方案在难治性急性髓系白血病治疗中的应用[J].中国临床医学,2009,16(1):123-125. 被引量：3
3Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues[ M]. 4ed. Lyon: In- ternational Agency for Research on Cancer,2008:130 -139.
4Cheson B D, Bennett J M, Kopecky K J, et al. Revised recommenda- tions of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic TriMs in Acute Myeloid Leukemia [ J]. J Clin Oncol, 2003,21 (24) :4642 -4649.
5Szer J. The prevalent predicament of relapsed acute myeloid leukemia [ J ]. Hematology Am SocHematolEduc Program,2012, 2012:43 - 48.
6刘晶,马军.老年急性髓系白血病患者治疗的新进展[J].临床血液学杂志,2009,22(5):511-514. 被引量：14
7Mural M, Toyota M, Satoh A, et al. Aberrant DNA methylation associ- ated with silencing BNIP3 gene expression in haematopoietictumours [J]. Br J Cancer, 2005,92(6): 1165 -1172.
8Hasegawa D, Manabe A, Kubota T, et al. Methylation status of the p15 and p16 genes in paediatricmyelodysplastic syndrome and juvenile myelomonocytic leukemia [ J ]. Br J Haematol, 2005, 128 ( 6 ) : 805 -812.
9Jiang Y, Dunbar A, Gondek L P, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML[J]. Blood, 2009, 113(6) :1315 - 1325.
10Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, ran- domized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of old patients with newly diagnosed acute myeloid leukemia[ J]. J ClinOncol, 2012,30 (21) :2670 - 2677.

二级参考文献29

1何学鹏,杨科.中、大剂量阿糖胞苷治疗急性髓细胞白血病新进展[J].中国实用内科杂志,1995,15(9):554-555. 被引量：4
2Oheda M, Hattori K, Kuboniwa H, et al. O-linked sugar chain of human granulncyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity[J]. J Biol Chen, 1990 ,265 : 11432.
3Dong F, pouwel K, Hoefsloot HL, et al. The C-terminal cytoplasmic region of the granulocyte colony-stimulating factor receptor mediates apoptosis in maturation incompetent routine cells[J]. Exp Hematol, 1996,24:214.
4Tsuruta T, Tani K, Shimane M, et al. Effects of myrloid cell groath factors on alkakine phosphatase, myrloperixidase, defensin and granuloeyte cotonystimulating factor receptor mRNA expression in haemopoietic cells of normal individuals and myeloid disorders[J]. Br J Haematol, 1996,92:9.
5Santini V,Colomat PH, Delwel R,et al. Induction of granulocyte maturation in acute myeloid leukemia by G-CSF and retinoic aeid. Leukemia[J]. Res,1991,15:341.
6Bin H,Kozo Y. Effects of colony-stimulating factors on neutrophil apoptosis:possible roles at inflammation site[J]. Int J Hematol, 1997,66 : 179.
7Bai A,Kojima H, Hori M,et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apotosis in myeloid leukemia cells[J]. Exp Hematol,1999,27(2) ;259-265.
8Reuter C, Schleyer E, Rolf C, et al. Differential effect of GMCSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts[J]. Leukemia, 1997,11 : 561-571.
9Saito K, Nakamura Y, Aoyagi Y, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor(CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia(AML) and previously untreated elderly patients with AML, secondary AML,and refractory anemia with excess blasts in transformation[J]. Int J Hematol,2000,71 (3):238-244.
10Katagiri T, Miyazawa K, Nishimaki J, et al. Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro[J]. Leuk Lymphoma,2000,39(1-2) : 173-184.